Armed robbery in Revesby1d
Tarlatamab OK'd for Adult Small Cell Lung Cancer
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 31 December 2024, approved the medicine tarlatamab ...
Amgen gets U.K. approval for tarlatamab for small cell lung cancer
The U.K.'s Medicines and Healthcare products Regulatory Agency has approved Amgen's (NASDAQ:AMGN) tarlatamab, also known as ...
pharmaphorum10d
FDA starts speedy review of Amgen’s lung cancer BiTE therapy
At the moment, Amgen looks like it has a sizeable lead in the DLL3 category, with other potential indications for tarlatamab, including neuroendocrine prostate cancer (in phase 1) and potentially ...
Amgen’s tarlatamab approved by MHRA for small cell lung cancer
The Medicines and Healthcare products Regulatory Agency of the United Kingdom announced it has approved the medicine tarlatamab, Imdyllytra, to ...
pharmaphorum7mon
Amgen adds BiTE to its cancer range as FDA clears Imdelltra
Tarlatamab has been approved under the Imdelltra ... and albumin and is in a phase 1/2 trial in neuroendocrine prostate cancer (NEPC) and other neuroendocrine neoplasms (NEN).
Hosted on MSN7mon
FDA approves Imdelltra for patients with extensive-stage small cell lung cancer
The U.S. Food and Drug Administration on Thursday approved a new drug to treat patients with an advanced form of deadly lung cancer. Importantly, tarlatamab (Imdelltra) is only for patients who ...